the aid library

LIST OPTIONS

Filter

995

Sort by:

Direction:

Download (1473)

View PDF (1140)

IMAI district clinician manual: hospital care for adolescents and adults: guidelines for the managementof illnesses with limited-resources. Vol. 1
recommended

World Health Organization WHO (2011) C_WHO

Volume 1 covers emergency triage assessment and treatment, and acute care for a severely ill or acutely injured patient for approximately the first 24 hours of care. It describes the clinical procedures commonly used in emergency and acute care, and gives a summary of the medicines used and the step... more

Download (251)

View PDF (274)

Руководство по оказанию помощи и лечению при хронической инфекции, вызванной вирусом гепатита С

World Health Organization WHO (2019) C_WHO

Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection

Download (487)

View PDF (984)

Management of physical health conditions in adults with severe mental disorders
recommended

World Health Organization WHO (2018) C_WHO

The global burden of disease due to mental disorders continues to rise, especially in low- and middle-income countries (LMIC). In addition to causing a large proportion of morbidity, mental disorders – especially severe mental disorders (SMD) – are linked with poorer health outcomes and increase... more

Download (173)

View PDF (1366)

French guidelines for the management of chikungunya (acute and persistent presentations), November 2014

F.Simona,E.Javellea ,A.Cabie, et al. (2015) CC

Recommandations francaises pour la prise enc harge du chikungunya Médecine e tmaladies infectieuses 45(2015)243–263

Download (168)

View PDF (204)

Guidance on the clinical management of acute and chronic harms of club drugs and novel psychoactive substances.

Abdulrahim, D.; and O. Bowden-Jones Novel Psychoactive Treatment UK Network (NEPTUNE) (2015) CC

Download (530)

View PDF (968)

Infection Prevention and Control Assessment Framework at the Facility Level
recommended

World Health Organization WHO (2018) C_WHO

The Infection Prevention and Control (IPC) Assessment Framework (IPCAF) is a tool to support the implementation of the World Health Organization (WHO) Guidelines on core components of IPC programmes at the acute health care facility level. The user should be familiar with the contents of these guide... more

Download (509)

View PDF (783)

Access to medicine Index 2022

Access to Medicine Foundation (2022) C2

Globally each year, millions of people suffer illness or lose their lives because the vaccines, medicines and diagnostic tests that they need are either unavailable or unaffordable – and this lack of access to medicine is acute in low- and middle-in- come countries (LMICs). While the COVID-19 pan... more

Download (745)

View PDF (5277)

Rapid Risk Assessment of Acute Public Health Events
recommended

World Health Organization 2012 (2011) C_WHO

This manual has been developed to guide rapid risk assessment of acute public health risks from any type of hazard in response to requests from Member States of the World Health Organization (WHO). The manual is aimed primarily at national departments with health-protection responsibilities, Nationa... more

Download (796)

View PDF (1543)

Impact of WASH Interventions during Disease Outbreaks in Humanitarian Emergencies: A systematic review protocol
recommended

Tufts University, Oxfam (2016) CC

In this review, the editors will investigate the impact of eight WASH interventions in preventing (reducing the risk of) and controlling outbreaks in LMIC, with particular focus on three diseases of current concern to the response community – cholera, Ebola, and Hepatitis E. Additionally, we will ... more

Download (119)

View PDF (161)

Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis (CDC)

Centers for Diseases Control and Prevention (2019) C_CDC

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of Tuberculosis Elimination Accessed: 08.10.2019

Download (483)

View PDF (989)

Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV
recommended

World Health Organization (WHO) (2022) C_WHO

Cryptococcal disease is one of the most common opportunistic infections among people living with advanced HIV disease and is a major contributor to severe illness, morbidity, and mortality, particularly in sub-Saharan Africa. These guidelines update the recommendations that were first released i... more

Download (167)

View PDF (366)

Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis

Centers for Disease Control and Prevention, National Center for HIVAIDS, et. al (2013) C_CDC

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Division of Tuberculosis Elimination.

Download (154)

View PDF (185)

Guidance on COVID-19 for the care of older people and people living in long-term care facilities, other non-acute care facilities and home care

World Health Organization WHO (2020) C_WHO

In response to the COVID-19 outbreak, this guidance provides information on infection and prevention control (IPC) for older people, their friends and families, carers, and healthcare providers. Anyone who manages, works, volunteers or provides care at any type of facilities where older people recei... more

Download (121)

View PDF (186)

Considerations and Principles for Shielding People at High Risk of Severe Outcomes from COVID-19

Social Science in Humanitarian Action (2020) CC

This brief considers the rationale for shielding individuals at high risk of severe disease or death from COVID-19 in low- and middleincome countries. It provides an overview of proposed approaches to shielding, discusses the categories of individuals who may be identified for shielding, and outline... more

Download (401)

View PDF (304)

National Guidelines on the Management of Moderate Acute Malnutrition for Children under Five Years

World Food Programme (WFP) (2016) C1

Manual of Operations First Edition 2016

Download (323)

View PDF (250)

Emergency Triage Assessment and Treatment Plus (ETAT+) - National Training Manual

Reproductive and Child Health Ministry of Health and Sanitation Sierra Leone (2017) CC

The purpose of this reference manual to support learning of ETAT + principles and to complement your clinical training and practice. The manual is for use before, during, and after an ETAT + course. This manual contains the necessary information to help you to: • Triage all sick children when th... more

Download (199)

View PDF (251)

WHO consolidated guidelines on tuberculosis - Module 5: Management of tuberculosis in children and adolescents
recommended

World Health Organization WHO (2022) C_WHO

The Updated guidelines on Management of tuberculosis in children and adolescents include new recommendations that cover diagnostic approaches for TB, shorter treatment for children with non-severe drug-susceptible TB, a new option for the treatment of TB meningitis, the use of bedaquiline and delama... more

Download (70)

View PDF (100)

Safety and monitoring for patients receiving Nirmatrelvir-ritonavir for COVID-19
recommended

World Health Organization WHO (2022) C_WHO

This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.

Download (100)

View PDF (96)

Financing Health for All: Increase, transform and redirect - The WHO Council on the Economics of Health for all - Council Brief No. 2

World Health Organisation (WHO) (2021) C_WHO

The world has been turned on its head by the coronavirus disease 2019 (COVID-19) pandemic. This has provided a stark wakeup call on the severe under-financing of health systems around the world. It has laid bare the inequalities and limitations in the capacities of countries at all levels of develop... more

Download (245)

View PDF (329)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

IMAI district clinician manual: hospital care for adolescents and adults: guidelines for the managementof illnesses with limited-resources. Vol. 1 recommended

Management of physical health conditions in adults with severe mental disorders recommended

Infection Prevention and Control Assessment Framework at the Facility Level recommended

Rapid Risk Assessment of Acute Public Health Events recommended

Impact of WASH Interventions during Disease Outbreaks in Humanitarian Emergencies: A systematic review protocol recommended

Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV recommended

WHO consolidated guidelines on tuberculosis - Module 5: Management of tuberculosis in children and adolescents recommended

Safety and monitoring for patients receiving Nirmatrelvir-ritonavir for COVID-19 recommended